Preclinical characterization of a Selective FGFR2/3 inhibitor, GSC000829

被引：0
|
作者：
Han, T. [1 ]
Fu, D. [1 ]
Cheng, T. [1 ]
Xia, Y. [1 ]
Hu, Z. [1 ]
Yang, F. [1 ]
机构：
[1] Changchun GeneSci Pharmaceut Co Ltd, Chem Drug Res & Dev, Shanghai, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114647
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB112
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [11] Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers
    Dardenne, Etienne
    Padilla, Fernando
    Rasmussen, Sara
    Yang, Shao Ning
    Mentes, Ahmet
    Ogawa, Luisa Shin
    Trombino, Anthony
    Romashko, Darlene
    Chevtsova, Maria
    Thakur, Shalabh
    Buck, Elisabeth
    Roberts, Christopher
    Lucas, Matthew
    Lin, Tai-An
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [12] Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers
    Dardenne, E.
    Padilla, F.
    Rasmussen, S.
    Yang, S. N.
    Mentes, A.
    Ogawa, L. S.
    Fiorenza, R.
    Trombino, A.
    Smith, S.
    Romashko, D.
    Ishiyama, N.
    Chevtsova, M.
    Thakur, S.
    Rosfjord, E.
    Buck, E.
    Roberts, C.
    Lucas, M.
    Lin, T-A.
    ANNALS OF ONCOLOGY, 2021, 32 : S15 - S15
  • [13] Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models
    Wu, Xiao Yu
    Xu, Hao
    Wu, Zhen Feng
    Chen, Che
    Liu, Jia Yun
    Wu, Guan Nan
    Yao, Xue Quan
    Liu, Fu Kun
    Li, Gang
    Shen, Liang
    ONCOTARGET, 2015, 6 (42) : 44563 - 44578
  • [14] FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
    Xie, Liang
    Su, Xinying
    Zhang, Lin
    Yin, Xiaolu
    Tang, Lili
    Zhang, Xiuhua
    Xu, Yanping
    Gao, Zeren
    Liu, Kunji
    Zhou, Minhua
    Gao, Beirong
    Shen, Danping
    Zhang, Lianhai
    Ji, Jiafu
    Gavine, Paul R.
    Zhang, Jingchuan
    Kilgour, Elaine
    Zhang, Xiaolin
    Ji, Qunsheng
    CLINICAL CANCER RESEARCH, 2013, 19 (09) : 2572 - 2583
  • [15] Preclinical activity of Debio 1347, an oral selective FGFR1, 2, 3 inhibitor, in models harboring FGFR alterations
    Chessex, A. Vaslin
    Moulon, C.
    Nicolas-Metral, V.
    Menetrey, A.
    Maby-El Hajjami, H.
    Rigotti, S.
    Zanna, C.
    Vuagniaux, G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 177 - 178
  • [16] Preclinical characterization of LOX-24350, a highly potent and isoform-selective FGFR3 inhibitor
    Ballard, Joshua A.
    Kercher, Timothy
    Abraham, David
    Brecht, Ryan
    Brooks, Nathan A.
    Buckles, Thomas
    Bume, Desta
    Busha, David
    Cedervall, Ernst Peder
    Condroski, Kevin
    Ebata, Kevin
    Gharbi, Severine Isabelle
    Hazlitt, Robert
    Morales, Tony
    Patel, Nisha
    Podoll, Jessica
    Urkalan, Kaveri
    Villalain, Sandra Gomez
    Walls, Shane
    Watson, Faith
    Yang, Peiyi
    Brandhuber, Barbara J.
    Andrews, Steven W.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [17] 3HP-2827-high selective inhibitor of FGFR2, a best-in-class therapy for FGFR2-driven solid tumors
    Liu-Chen, Susan S.
    Lin, Jufang
    Hu, Jingyu
    Liu, Yanchao
    Zhang, Weibo
    Zhang, Zhixiong
    Ding, Yan
    Liu, Jinqiu
    Chen, Kevin
    Hu, Shaojing
    CANCER RESEARCH, 2024, 84 (06)
  • [18] Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies
    Tyulyandina, Alexandra
    Harrison, Daniel
    Yin, Wei
    Stepanova, Evgenia
    Kochenkov, Dmitry
    Solomko, Eliso
    Peretolchina, Nina
    Daeyaert, Frits
    Joos, Jean-Baptiste
    Van Aken, Koen
    Byakhov, Mikhail
    Gavrilova, Evgenia
    Tjulandin, Sergei
    Tsimafeyeu, Ilya
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 127 - 133
  • [19] Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies
    Alexandra Tyulyandina
    Daniel Harrison
    Wei Yin
    Evgenia Stepanova
    Dmitry Kochenkov
    Eliso Solomko
    Nina Peretolchina
    Frits Daeyaert
    Jean-Baptiste Joos
    Koen Van Aken
    Mikhail Byakhov
    Evgenia Gavrilova
    Sergei Tjulandin
    Ilya Tsimafeyeu
    Investigational New Drugs, 2017, 35 : 127 - 133
  • [20] Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
    Liao, Rachel G.
    Jung, Joonil
    Tchaicha, Jeremy
    Wilkerson, Matthew D.
    Sivachenko, Andrey
    Beauchamp, Ellen M.
    Liu, Qingsong
    Pugh, Trevor J.
    Pedamallu, Chandra Sekhar
    Hayes, D. Neil
    Gray, Nathanael S.
    Getz, Gad
    Wong, Kwok-Kin
    Haddad, Robert I.
    Meyerson, Matthew
    Hammerman, Peter S.
    CANCER RESEARCH, 2013, 73 (16) : 5195 - 5205
12345